Cargando…

Humoral immunity for durable control of SARS-CoV-2 and its variants

The coronavirus disease 2019 (COVID-19) pandemic is ongoing because of the repeated emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, highlighting the importance of developing vaccines for variants that may continue to emerge. In the present review, we discuss humor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kotaki, Ryutaro, Moriyama, Saya, Takahashi, Yoshimasa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834039/ https://www.ncbi.nlm.nih.gov/pubmed/36631890 http://dx.doi.org/10.1186/s41232-023-00255-9

Ejemplares similares

Heterologous SARS-CoV-2 spike protein booster elicits durable and broad antibody responses against the receptor-binding domain
por: Takano, Tomohiro, et al.
Publicado: (2023)

Immune evasion and chronological decrease in titer of neutralizing antibody against SARS-CoV-2 and its variants of concerns in COVID-19 patients
por: Takeshita, Masaru, et al.
Publicado: (2022)

Population-based study of the durability of humoral immunity after SARS-CoV-2 infection
por: Peterhoff, David, et al.
Publicado: (2023)

Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination
por: Mantus, Grace, et al.
Publicado: (2022)

Durable T-cellular and humoral responses in SARS-CoV-2 hospitalized and community patients
por: Mohn, Kristin G.-I., et al.
Publicado: (2022)

Immune recall improves antibody durability and breadth to SARS-CoV-2 variants
por: Chen, Yuezhou, et al.
Publicado: (2022)

Non-Omicron breakthrough infection with higher viral load and longer vaccination-infection interval improves SARS-CoV-2 BA.4/5 neutralization
por: Miyamoto, Sho, et al.
Publicado: (2023)

SARS-CoV-2 Omicron-neutralizing memory B-cells are elicited by two doses of BNT162b2 mRNA vaccine
por: Kotaki, Ryutaro, et al.
Publicado: (2022)

Humoral immune durability of IgG for anti-SARS-CoV-2 in the normal pregnant women in Wuhan, China
por: Ma, Hongwen, et al.
Publicado: (2021)

Structural delineation and computational design of SARS-CoV-2-neutralizing antibodies against Omicron subvariants
por: Moriyama, Saya, et al.
Publicado: (2023)

Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern
por: McNamara, Ryan P., et al.
Publicado: (2023)

Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity
por: Ripperger, Tyler J., et al.
Publicado: (2020)

Impact of Inflammatory Bowel Disease Therapies on Durability of Humoral Response to SARS-CoV-2 Vaccination
por: Charilaou, Paris, et al.
Publicado: (2022)

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
por: Garcia-Beltran, Wilfredo F., et al.
Publicado: (2021)

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
por: Garcia-Beltran, Wilfredo F., et al.
Publicado: (2021)

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
por: Garcia-Beltran, Wilfredo F., et al.
Publicado: (2021)

Evasion of vaccine-induced humoral immunity by emerging sub-variants of SARS-CoV-2
por: Koyama, Takahiko, et al.
Publicado: (2022)

Breakthrough infection shapes humoral immunity against SARS-CoV-2 Omicron Variant
por: Zhang, Yuwei, et al.
Publicado: (2023)

Humoral Immune Response to SARS-CoV-2 in Iceland
por: Gudbjartsson, Daniel F., et al.
Publicado: (2020)

CD62L expression marks SARS-CoV-2 memory B cell subset with preference for neutralizing epitopes
por: Onodera, Taishi, et al.
Publicado: (2023)

Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection
por: Cromer, Deborah, et al.
Publicado: (2021)

GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial
por: Capone, Stefania, et al.
Publicado: (2023)

SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection
por: Havervall, Sebastian, et al.
Publicado: (2022)

Durability of Immunity to SARS-CoV-2 and Other Respiratory Viruses
por: Siggins, Matthew K., et al.
Publicado: (2021)

Pre-existing anti-HCoV-OC43 immunity influences the durability and cross-reactivity of humoral response to SARS-CoV-2 vaccination
por: Hu, Caiqin, et al.
Publicado: (2022)

Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants
por: Miyamoto, Sho, et al.
Publicado: (2022)

Development of SARS-CoV-2 variant protein microarray for profiling humoral immunity in vaccinated subjects
por: Ho, Tzong-Shiann, et al.
Publicado: (2022)

Comprehensive Humoral and Cellular Immune Responses to SARS-CoV-2 Variants in Diverse Chinese Population
por: Li, Jiwei, et al.
Publicado: (2022)

A multicomponent intranasal adjuvant drives durable humoral, cellular, and mucosal immune responses to SARS-CoV-2 in young and aged mice
por: Jangra, Sonia, et al.
Publicado: (2023)

Realization of humoral immunity against SARS-CoV-2 infections
por: Lin, Yong, et al.
Publicado: (2021)

Mechanisms of Dysregulated Humoral and Cellular Immunity by SARS-CoV-2
por: Taefehshokr, Nima, et al.
Publicado: (2020)

Humoral and adaptive immune responses to the SARS-CoV-2 vaccine
por: Rizzo, Roberta, et al.
Publicado: (2022)

Waning and boosting of functional humoral immunity to SARS-CoV-2
por: Tong, X., et al.
Publicado: (2022)

Immunological imprinting of humoral immunity to SARS-CoV-2 in children
por: Dowell, Alexander C., et al.
Publicado: (2023)

Longitudinal Analysis of Neutralizing Potency against SARS-CoV-2 in the Recovered Patients after Treatment with or without Favipiravir
por: Shinada, Kanako, et al.
Publicado: (2022)

An intranasal vaccine durably protects against SARS-CoV-2 variants in mice
por: Hassan, Ahmed O., et al.
Publicado: (2021)

Distinct immune cell dynamics correlate with the immunogenicity and reactogenicity of SARS-CoV-2 mRNA vaccine
por: Takano, Tomohiro, et al.
Publicado: (2022)

Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination
por: Caniels, Tom G., et al.
Publicado: (2021)

Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines
por: Cao, Yunlong, et al.
Publicado: (2021)

Corrigendum to “Comprehensive Humoral and Cellular Immune Responses to SARS-CoV-2 Variants in Diverse Chinese Population”
por: Li, Jiwei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hremhhnu46famv5nmic598clqg